Krill harvester and processor Aker BioMarine has signed an agreement with Trofi Nutrional to develop medical food products targeting Alzheimer's disease, male infertility and gestational diabetes, in addition to pre-natal supplements in the United States.

The products will use AkerBioMarine's method of producing EPA and DHA from krill, bound with Lysophosphatidylcholine, a molecule with the unique ability to be transported across the blood brain barrier and containing important nutrients for the brain functioning.

This product, Lysoveta, was developed by AkerBioMarine in November 2020 and this newly announced partnership takes it a step closer to commercialization in the lucrative brain-health market.